First Efficacy and Safety Results with the Antibody Containing Leukocyte Inhibition Module in Cardiac Surgery Patients with Neutrophil Hyperactivity
Authors:
- Jindrich CinatlJCJindrich Cinatl
- Rubens T BarrosRBRubens T Barros
- Ana C B LisboaALAna C B Lisboa
- Carla F F GenevciusCGCarla F F Genevcius
- Stefan MargrafSMStefan Margraf
- Ieda FrancischettiIFIeda Francischetti
- Gerhard OremekGOGerhard Oremek
- Joachim WindolfJWJoachim Windolf
- Andreas SimonASAndreas Simon
- Anton MoritzAMAnton Moritz
- José Bitu-MorenoJBJosé Bitu-Moreno
- 1 March 2005
- journal article
- clinical trial
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 51 (2) , 144-147
Abstract
Systemic administration of immune modulating antibodies may play an important role in reducing neutrophil hyperactivity, for example, in patients undergoing cardiac surgery with extracorporeal circulation or in trauma patients. However, this strategy has extremely high costs and is often associated with severe adverse effects. We developed the Leukocyte-Inhibition-Module (LIM), an extracorporeal circulation (ECC) device housing a polyurethane matrix with covalently bound Fas (CD95; APO-1) stimulating antibodies to rapidly prevent neutrophil hyperactivation. A feasibility study with 14 patients undergoing cardiac surgery with the use of immunogenic ECC without (n = 5) and with (n = 9) LIM (venous line) was performed. Our data show that the usually observed ECC associated perioperative increase in neutrophils (control) was prevented by LIM (p = 0.023). Moreover, the increase of the proinflammatory markers tumor necrosis factor (TNF)-alpha and polymorphonuclear elastase was limited by LIM (p = 0.038 and p = 0.002). In both groups, no significant changes in liver enzymes or in clotting were detected after surgery, and up to 12 months follow up, no unusual complications were reported. This study shows for the first time to our knowledge the feasibility, efficacy, and safety of a new cost effective, immune management strategy in patients with aberrant immune activation by exposing the blood stream to immobilized agonistic anti-Fas antibodies.Keywords
This publication has 14 references indexed in Scilit:
- In vivo inhibition of neutrophil activity by a FAS (CD95) stimulating module: arterial in-line application in a porcine cardiac surgery modelThe Journal of Thoracic and Cardiovascular Surgery, 2004
- Pre–B cell colony–enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsisJournal of Clinical Investigation, 2004
- Inhibition of neutrophil activity in cardiac surgery with cardiopulmonary bypass: a novel strategy with the leukocyte inhibition modulePerfusion, 2004
- Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndromeThe Journal of Pathology, 2003
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- Decreased Neutrophil Adhesion to Human Cytomegalovirus-Infected Retinal Pigment Epithelial Cells Is Mediated by Virus-Induced Up-Regulation of Fas Ligand Independent of Neutrophil ApoptosisThe Journal of Immunology, 2000
- Efficiency and safety of leukocyte filtration during cardiopulmonary bypass for cardiac surgeryTransfusion Science, 1999
- Induction of Apoptosis and Pulmonary Fibrosis in Mice in Response to Ligation of Fas AntigenAmerican Journal of Respiratory Cell and Molecular Biology, 1997
- Macrophage Engulfment of Apoptotic Neutrophils Contributes to the Resolution of Acute Pulmonary Inflammation In VivoAmerican Journal of Respiratory Cell and Molecular Biology, 1995
- Lethal effect of the anti-Fas antibody in miceNature, 1993